Ozempic and Hair Loss: Scientists Figure Out Why Weight-Loss Drugs May Cost Men Their Hair

Semaglutide-based drugs such as Ozempic and Wegovy have long been linked to hair loss, but doctors have attributed the side effect solely to the stress that comes with rapid weight loss. A new study by geneticists at NYU Langone Health suggests the biological mechanism may be far more complex: stimulating the GLP-1 receptor may directly fuel the development of classic male pattern baldness.

In the study, published in the Journal of Investigative Dermatology, the authors used Mendelian randomization. Instead of observing patients directly, they analyzed genetic databases covering more than 205,000 men, assessing the lifetime impact of variations in the GLP1R gene — the very receptor that the popular diabetes and obesity injections interact with.

The calculations showed that genetically driven higher GLP1R activity is associated with roughly a 7% increase in the likelihood of androgenetic alopecia. The link held even after adjusting for testosterone levels, blood pressure and measures of insulin resistance, according to NYU Langone Health.

Temporary Diet Stress or Irreversible Thinning of the Follicles

The fact that hair thins while taking these drugs is no secret to endocrinologists. In the official FDA label for Wegovy, hair loss is listed directly among adverse events: at a 2.4 mg dose, 3.3% of trial participants reported it, versus 1% in the placebo group. And a meta-analysis of interventional studies in the PubMed database put the average rate of the problem at 3.9%.

The key difference, however, lies in the type of hair loss. It was previously thought that patients experienced only telogen effluvium. That is a temporary reaction to a calorie deficit, a lack of micronutrients and the physiological stress of rapid weight loss: follicles go into a mass “dormant” phase, but hair usually grows back on its own a few months after the diet stabilizes.

The newly found link to the GLP1R receptor points to androgenetic alopecia — an inherited, progressive degradation of the hair follicles driven by hormones. If the drug really does accelerate that pathway, the lost hair will not come back after the injections stop without specialized trichological treatment.

What This Means for Patients

The scientists urge people not to jump to conclusions or abandon their prescribed therapy. The work is fundamental in nature and does not yet allow an individual risk to be calculated for any one person. In addition, the underlying genetic databases consisted mostly of men of European descent.

The authors plan to test the hypothesis in practice: tracking trichological markers in people already on GLP-1 therapy, and finding out whether this hidden mechanism affects women as well.